Loading...
•
Jun 30, 2022
Keros Q2 2022 Earnings Report
Keros Therapeutics experienced increased research and development efforts and infrastructure expenses, leading to a net loss.
Key Takeaways
Keros Therapeutics reported a net loss of $27.3 million for the second quarter of 2022, driven by increased research and development and infrastructure expenses. The company's cash and cash equivalents totaled $215.6 million as of June 30, 2022, expected to fund operations into Q3 2024.
KER-050 Phase 2 study showed meaningful responses in MDS patients, with 44% of high transfusion burden patients achieving transfusion independence.
KER-012 Phase 1 data exhibited encouraging treatment profile with improvements in bone formation biomarkers.
Cash position was strengthened, extending cash runway into Q3 2024.
Keros remains on track to report additional data from KER-050 and KER-012 studies later this year.
Forward Guidance
Keros expects that the cash and cash equivalents it had on hand at June 30, 2022 will fund its operating expenses and capital expenditure requirements into the third quarter of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...